Navigation Links
Accelovance Expansion Continues with Acquisition of Radiant Development, the CRO Division of Radiant Research
Date:3/6/2013

ROCKVILLE, Md., March 6, 2013 /PRNewswire-USNewswire/ -- Accelovance, Inc. announced today the acquisition of Radiant Development, the CRO division of Radiant Research. This is the latest development in an expansion strategy by the Maryland based CRO that caters to Biotech and small/mid Pharma Sponsors. Terms of the transaction were not disclosed. 

Accelovance is a patient centric CRO offering innovative solutions to meet the needs of its clients. Much of the company's CRO growth has been in the vaccine, infectious disease, and oncology markets. The addition of Radiant Development broadens Accelovance's ability to provide high quality services across a range of therapeutic areas. Radiant Development has performed studies in areas including cardiovascular, men's and women's health, rheumatology, dermatology, oncology and medical device.  Radiant Development also has specialized expertise in consumer health and nutrition.

"We are thrilled to have 100% of the Radiant team led by Vita Lanoce as part of our company.  Core values focused on meeting our client needs, open communication and relationships built on honesty and trust are important similarities between our organizations," remarked Stephen J. Trevisan , Accelovance President and Chief Executive Officer.

Operating out of locations in Stuart, Florida, Chicago, Illinois, and Durham, North Carolina, Radiant Development has managed over 200 research studies since its inception.  Additionally, the company has established strategic partnerships in Europe and Asia to offer clients global study capabilities.  Radiant Development will operate as a division of Accelovance, providing full service clinical capabilities including: project management and clinical monitoring, medical, safety and pharmacovigilance, regulatory consulting, medical writing, data management and statistical services.

"With a shared vision of an innovative approach to execution, exceptional customer service, and focus on providing value to our clients, Radiant Development is delighted to join forces with Accelovance to offer expanded leading edge service solutions to our clients," said Vita Lanoce , Senior Vice President of Development.

Current customers, employees and stake holders of Radiant Development should expect the continued high level of quality, service and performance they are accustomed to receiving.  This includes an ongoing, preferred provider relationship with the Radiant Research and Clinical Research Advantage site network.     

About Accelovance

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies.  The Company was recognized as "Best CRO" with consecutive Industry Excellence awards in 2009, 2010 and 2011. Accelovance tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor's needs.  Accelovance has a 100% owned subsidiary providing CRO services in China.  These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.  Additionally, Accelovance offers six (6) wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to therapeutically aligned studies.

For more information, visit the company's website at http://www.accelovance.com.  

About Radiant Development

Based in Stuart, Florida, Chicago, Illinois and Durham, North Carolina, Radiant Development is a full service CRO offering clinical development services to the biopharmaceutical, biotech, medical device, nutrition and consumer products industries. Our experienced professionals assess and match client's clinical development needs with the services their program requires for success.  

Media Contact:
Garrett D. Smith
Phone: 240.238.4914
gsmith@accelovance.com 


'/>"/>
SOURCE Accelovance
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelovance Expands Oncology Leadership with the Addition of Ralph Boccia, MD as Oncology Medical Director
2. Ultragenyx Relocates Company Headquarters to Support Operational Expansion
3. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
4. HealthEd Taps Kelemen to Lead West Coast Expansion
5. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
6. PolyOne Announces Expansion in Costa Rica with Healthcare-Focused Distribution Services
7. Anatabloc® Retail Expansion with GNC Complete: Product Now Available at all GNC Corporate Stores and GNC.com
8. Medifast Announces International Expansion Into Mexico Through Strategic Partnership with Medix
9. Sentry BioPharma Services Invests in Global Clinical Supply Services with -45C Freezer Expansion
10. iBio Announces Important Expansion of its Intellectual Property Portfolio: Allowance of Patent for Anthrax Vaccines and Further Application of Modulator Platform
11. Canada-based Radimetrics Announces Expansion to Scotland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results ... and updated its financial outlook for fiscal 2017. ... third quarter, Hill-Rom reported earnings of $0.09 per diluted ... prior-year period. These results reflect after-tax special items, including ... to the non-cash write-down of assets associated with the ...
(Date:7/27/2017)... Pa., July 27, 2017  West Pharmaceutical Services, Inc. ... results for the second-quarter 2017 and updated financial guidance ... Second-Quarter 2017 Highlights Reported net ... over the prior-year quarter. Net sales at constant currency ... reported-diluted EPS was $0.51, compared to $0.60 in the ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... “Three Narrow Roads”: a vivid ... creation of published author, Rev. Dr. Burnett King Sr., is currently the pastor-teacher-visionary at ... of the Faith Track Club, Inc., a track-and-field program geared towards youth. , King ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Depressed: Super Heroes of the Bible”: ... upon the stories and the relevance these tales may have on the reader’s life. ... a former special education teacher, Jessica spends much of her time enjoying nature and ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Kingdom Mandate for Kingdom Builders”: a call to ... for Kingdom Builders” is the creation of published author, John F. McGeorge, Jr. ... a missionary in 1983. He spent three decades training pastors and Christian leaders. ...
(Date:8/18/2017)... ... 2017 , ... “Steve the Snake”: an entertaining and moral-based short story about ... published author, Harold Flash Haskins Jr., a husband, father and grandfather who served as ... “I write moral-based short stories for children and teens. My goal is to teach ...
(Date:8/17/2017)... ... 2017 , ... Riccobene Associates Family Dentistry, the Research Triangle’s ... its family of practices. Residents of Goldsboro will be able to experience the ... , Riccobene Associates Family Dentistry, founded by Dr. Michael Riccobene in 2000, prides ...
Breaking Medicine News(10 mins):